Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney...
Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity Castle...
Castle’s second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical use value in patients...
The consensus guidelines were drafted by a multidisciplinary panel of radiation oncologists and dermatologists/Mohs micrographic surgeons with...
Study data show that one-third of the IDgenetix-guided medication recommendations were due to drug-drug interactions and lifestyle factors...
Castle’s presentations at AAD include the latest findings from the Company’s ongoing collaboration with the National Cancer Institute’s...
Largest study of gene expression profile testing in patients with high-risk cutaneous squamous cell carcinoma (SCC) supports test’s ability to...
Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test...
Study results, which include 5,651 patients in the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.